Claims databases consisting of routinely collected longitudinal records of medical expenditures are increasingly utilized for estimating expected medical costs of patients with a specific condition. Survival data of the patients of interest are usually highly censored, and observed expenditures are incomplete. In this study, we propose a survival-adjusted estimator for estimating mean lifetime costs, which integrates the product of the survival function and the mean cost function over the lifetime horizon. The survival function is estimated by a new algorithm of rolling extrapolation, aided by external information of age-and sex-matched referents simulated from national vital statistics. The mean cost function is estimated by a weighted average of mean expenditures of patients in a number of months prior to their death, of which the number could be determined by observed costs in their final months, and the weights depend on extrapolated hazards. We evaluate the performance of the proposed approach in comparison with that of a popular method using simulated data under various scenarios and 2 cohorts of intracerebral hemorrhage and ischemic stroke patients with a maximum follow-up of 13 years and conclude that our new method estimates the mean lifetime costs more accurately.
| INTRODUCTION
Accurate estimates of expected lifetime survival and lifetime medical costs are especially important to policymakers responsible for justifying the value of efforts in preventing a specific disease. Because more and more health care data arising from insurance claims databases have become available in most developed countries, it is increasingly feasible to obtain estimates of lifetime survival and lifetime medical costs using these claims data. Survival data of patients with some diseases of interest are usually highly censored, however, and observed expenditures are incomplete. The survival-adjusted estimator proposed by Lin, Feuer, Etzioni, and Wax (1997) was the first attempt to analyze censored medical cost data for estimating average total costs. The estimator is based on dividing the maximum follow-up time into a number of small intervals. The mean total cost for the follow-up time period is estimated by the sum of the mean costs for each time interval within the time period, weighted by the survival probability at the beginning of each interval. Theoretically, the estimator is unbiased when the intervals become infinitesimally small (O'Hagan & Stevens, 2004) . When aggregated data are available only for large time intervals, however, ignoring censoring within the intervals may cause a biased estimate. To deal with the problem of censoring within large intervals, Bang and Tsiatis (2000) proposed an alternative estimator of weighting the complete case, with the inverse of survival probability of censoring as the weight for each time interval. Basu and Manning (2010) further improved the consistency of the survival-adjusted estimator with a focus on explicitly separating the marginal effect of the covariate on total costs into one portion related to survival and another related to costs. That is, the expected cost during a time interval is written as a weighted sum of mean costs for those dying and not dying in the interval, with the hazard of death during the time interval and one minus the hazard as the two weights. Researchers also have proposed parametric models, which include relevant covariates to obtain more accurate estimates of the hazards and the two mean costs within the intervals. When applying these popular methods to estimate the effects of treatment on cost using observational data, they may be subject to bias if there are unmeasured confounders. Handorf, Bekelman, Heitjan, and Mitra (2013) further proposed methods for assessing the potential magnitude of such biases. An overview of these popular methods and related literature can be found in Basu and Manning (2010) and Wijeysundera, Wang, Tomlinson, Ko, and Krahn (2012) .
These popular estimators were proposed to deal with random censoring times and costs for improving the accuracy of cumulative medical cost estimates over a restricted time period, but they do not extrapolate the estimates beyond the maximum follow-up time of the observed data. The Etzioni method (Etzioni, Ramsey, Berry, & Brown, 2001 ) was the first to extend the survival-adjusted estimator beyond the observable time horizon by including both extrapolation of survival and mean costs beyond the maximum follow-up time. This method extrapolates the survival function in a conventional way by using the best fitted Weibull model from the observed survival data. The extrapolated hazards are further used with average annual expenditures of patients in their final year and average annual expenditures in years prior to their final year to estimate annual mean costs beyond the follow-up time. The expected lifetime cost is obtained by summing the product of the estimated survival and cost functions over the lifetime horizon. Hence, accuracy of the survival extrapolation is critical to the expected lifetime cost estimate. Parametric models perfectly fitted to the observed survival data, however, may not guarantee a reasonably long extrapolation when the censoring rate is high (Jackson, Stevens, Ren, et al., 2016) . Hence, it is desirable to modify the Etzioni method with reliable and robust methods for extrapolating the survival function. Hwang and Wang (1999) proposed borrowing external information from an age-and sex-matched reference population to aid the survival extrapolation of an index cohort. The curve of logit transformation of the relative survival between the index cohort and the reference population would follow an approximately straight line if the excess hazard of the patients remains constant over time (Fang, Chang, Hsu, et al., 2007) . This method has been successfully validated with simulation data and has been used to analyze real data in several studies (e.g., Cucchetti, Trevisani, Bucci, et al., 2016 , Hung et al., 2011 , H. Y. , Yang, Lee, Hsu, et al., 2012 Yang, Lai, Chang, et al., 2014) . The assumption of an excess constant hazard, however, is usually untestable with a limited observed time period, because how closely the curve of logit-transformed relative survival approaches a straight line is uncertain. In this study, we propose a new approach without the assumption of an excess constant hazard to improve Hwang and Wang's (1999) survival extrapolation method by using restricted cubic splines models to predict the curve beyond the maximum follow-up time, step-by-step.
The mean cost function in the Etzioni method can be represented as the weighted average monthly expenditure of patients in their final 12 months prior to death and the average monthly expenditure in the months prior to their final year. Etzioni et al. (2001) had made the assumption that patients' expenditures would be at a constant level over time after stabilization and start increasing in the 12 months prior to their death. The assumption seems reasonable, but when exactly the costs begin to increase may be quite different among people with different diseases and conditions. In this study, we will also modify the mean cost function in the Etzioni method by using the observed costs of patients in their final months to determine the time when the costs start changing. This paper is organized as follows. Section 2 describes the proposed methods in detail. In Section 3, we evaluate the performance and assess the sensitivity of the proposed methods using simulated data. In Section 4, we use population-based claims data from the Taiwan National Health Insurance program to establish two stroke cohorts, which we use to empirically validate the proposed method. We also report the estimates of lifetime direct medical costs of first-ever stroke patients. In the last section, we conclude with some remarks and discussions on the proposed method.
| METHODS
We assume that historical medical expenditures of patients in the study cohort with a specific disease are available from diagnosis to death or censored before a maximum follow-up time. We may divide the time course after the diagnosis into L intervals, denoted as (t j − 1 , t j ] for j = 1 , 2 , . . . , L, where t j is the right end point of the jth interval, t 0 = 0 is the day of diagnosis, and t L is the first time point beyond which the survival rate of the disease cohort is zero, that is, everyone has died. The accumulated cost paid for the diagnoses for confirmation of the disease may be counted in an additional interval (t −1 , t 0 ], where t −1 is often a few days before confirmation of the disease. For practical applications, we may consider intervals of various lengths depending on data availability. In this study, we set the duration equal to 1 month. That is, t j is the last day of the jth month after onset. Let c ij be the total medical expenditure claimed at the jth interval (t j − 1 , t j ] for the ith patient who has been completely observed during the time interval for j = 0 , 1 , . . . , L. Note that c ij = 0 when t j − 1 is larger than the ith patient's survival time after diagnosis. The lifetime cost claimed by the ith patient is Cost i ¼ ∑ L j¼0 c ij when the case is not censored. Similar to Equation 3 of Basu and Manning (2010) , the expected lifetime cost of the index cohort can be presented as
where S(t j ) is the mean survival rate of the cohort, and C(t j ) is the mean costs for subjects alive at time t j − 1 and living through t j or dying within the interval. This popular presentation of Equation 1 is important, as it provides us a simple way of estimating the expected lifetime medical cost for a disease cohort by plugging the estimates of monthly survival rates and estimates of monthly mean costs of the living subjects, which can be estimated separately, into the summation. We call Equation 1 with estimates of survival and mean cost functions a survival-adjusted cost estimator. We will describe the details of derivations of the two estimates of the complete survival and mean cost functions of living subjects in the following two subsections. The uncertainty of the estimate of life expectancy and expected lifetime cost can be estimated using bootstrap methods. We use methods of sampling with replacements to generate N, say 200, bootstrap samples of survival and samples of cost records of the same sample sizes from the original observed data. For each bootstrap sample, we calculate estimates of life expectancy and expected lifetime cost. With N sets of life expectancy and expected lifetime cost estimates, we can calculate sample standard deviations and the 2.5 and 97.5 percentiles to obtain 95% confidence intervals (CI) of life expectancy and the expected lifetime cost estimate.
| Extrapolation of the survival function
We start with a brief description of the survival extrapolation method proposed by Hwang and Wang (1999) to introduce the setup and notations. The Kaplan-Meier method or parametric models can be applied to the observed survival data of patients in an index cohort to estimate the survival function S(t| index) for the follow-up period of F months, from onset time t 0 to the end of follow-up t F . Monte Carlo methods are used to generate survival data of a reference population matched with the index cohort in age and sex. With the generated survival data, we obtain the survival function S(t| ref) of the reference population for t = t 0 , t 1 , . . . , t L . The relative survival W(t) is defined as the ratio between the survival functions of the index cohort and the reference population, which is often a decreasing function. The logit transformation of the relative survival function, denoted by logit W(t), often decreases quickly right after the onset, gradually approaches a straight line, and stays straight for a relatively long time before a change point near the end tail. The left extreme tail of logit W(t) corresponds to the period between onset and some time necessary for stabilization, which is usually observed. The right extreme tail corresponds to the time when the survival rate is near zero. With this linearity property of logit W(t) after some time point, Hwang and Wang (1999) proposed fitting a simple linear regression to logit W(t) during some short period [t a , t b ] near the end of follow-up t F , that is,
The prediction of logit W(t) beyond follow-up is given by logit b W t ð Þ≡b α þ b βt for t > t F , where b α and b β are the estimates of the intercept and slope in the linear regression model (Equation 2). Therefore, the extrapolation of the survival function can be obtained from the following:
It is clear that the extrapolation accuracy strongly depends on whether the true straight line has been identified before the end of follow-up. In practice, when the slopes of logit W(t) are still increasing at the end of follow-up, the fitted line based on the data in the chosen short period [t a , t b ] may deviate from the true one and result in a severe bias of survival extrapolation. Another potential problem is that the assumption of a constant excess hazard (Fang et al., 2007) , indicated by a straightened curve of logit W(t), is usually untestable. Instead of using Equation 2 with a short time period to predict a straight line of logit W(t) beyond the maximum follow-up t F , we can use a restricted cubic splines model to fit the flattened curve of logit W(t) using the whole follow-up period (Andersson, Dickman, Eloranta, Lambe, & Lambert, 2013 ). The fitted model is then used for the extrapolation of logit W(t) beyond follow-up. The restricted cubic spline function of H knots is defined as
where u + = u if u > 0 and u + = 0 if u ≤ 0, and a h is the position of the hth knot (Durrleman & Simon, 1989) . Similar to the methods proposed by Andersson et al. (2013) , the fitted restricted cubic splines model that gives a linear segment beyond the last knot can be used for extrapolating logit W(t) beyond t F . But if logit W(t) has no clear sign of approaching a straight line near the end of follow-up, the extrapolation of logit W(t) based on the fitted cubic splines model may come close to the true curve for only a few months ahead and not be accurate for a longer term prediction.
In this study, we take advantage of the accurate short-term extrapolation of restricted cubic splines models to guide logit W(t) forward step-by-step using the model updated data. Similar to the rolling forecast process for predicting the future over a set of time, we start with fitting a restricted cubic splines model to the data series of logit W(t) over the whole observed time period t 1 , t 2 , . . . , t F to predict logit W(t F + 1 ). The first observation logit W(t 1 ) would be dropped, and the predicted logit W(t F + 1 ) would be added to the end to form an updated data series with the same number of months. With the newly updated logit W(t) data series, the one-step-ahead prediction process would be repeated forward L − F times, where L is the final month of extrapolation. We summarize the proposed procedures as an algorithm called rolling extrapolation in the following.
| Rolling extrapolation algorithm
Step 2; otherwise, stop.
Note that we check whether the one-step extrapolation of logit W(t) is decreasing in Step 4 of the algorithm. If not, we refit the models with shorter series of data. When the extrapolation of logit W(t) beyond follow-up is successfully implemented, the extrapolation of the survival function in Equation 3 can be replaced by
Because logit W(t) often decreases sharply in the first several months after onset and gradually approaches a nearly straight line after some time, a cubic spline function with five knots will often be flexible enough for fitting the data scattered around a curve with a gradually decreasing curvature to near zero. The locations of the first and last knots may be set at time points corresponding to percentiles five and 90 of the time variable, and the other three are equally spaced in between the two ends (Durrleman & Simon, 1989) .
| Extrapolation of the mean cost function
Because medical expenditures are often higher during the time period near the end of life, we can incorporate this aspect to construct a more accurate estimate of the monthly mean costs. According to Basu and Manning's (2010) refined model, the mean aggregated costs in a time interval can be represented as a weighted average of mean costs of subjects who died in the time interval and the expected costs of subjects had they not died in that interval. When the time intervals are months, the monthly mean costs can be estimated by
where b h t j À Á is the estimated hazard of death during the interval (t j − 1 , t j ], given that the subject was observed to be alive at
are average costs in the jth month for individuals dying during that month and those living more than 1 month, respectively. Basu and Manning (2010) also pointed out that Equation 6 can be extended with additional K time intervals leading up to death, representing the different cost-accumulation process preceding death, but they did not give the details. As derived in the supplementary materials, we extend Equation 6 as
where b C k t j À Á ; k ¼ 0; 1; :::; K represents the estimated mean expenditure in the jth month for subjects who died during the (j + k) th month, and it can be interpreted as the average expenditure of subjects at time k months prior to their death. The correspond-
can be interpreted as the proportion of subjects who were alive in the jth month and lived until the (j + k)th month. And b
is the average costs in the jth month for individuals who did not die in the next K months.
In practice, we can estimate the hazards using the estimated complete survival function, that is,
can be calculated by taking the average of expenditures in the jth month for those subjects who died in the (j + k)th month if t j + k is smaller than or equal to t F , the end of follow-up. When t j + k is larger than t F , similar to the Etzioni method, we can assign a constant value
The constant D k , which is the mean expenditure of subjects at time k months prior to their death, is estimated using observed data in the last B months of follow-up as follows. We suggest starting with a value of B = 24 and an initial value of K, say 24. First, we identify subjects who died in month m during the last B months before t F , that is, m = F − B + 1 , . . . , F − 1 , F, to calculate the average of these subjects' expenditures in month m − k as an estimate of D k for k = 0 , 1 , . . . , K. Second, for subjects who were alive in month m for m = F − B + 1 , . . . , F − 1 , F, we calculate the average of these subjects' expenditures in month m − (K + 1) and denote it as d m .
We use the average of these d m 's to estimate D K þ . The final values of B and K will be determined by examining the time series plots of these D k estimates as follows. If the time series plot exhibits a high variation over the time, we may recalculate the D k estimates with a larger B so that the trend of the time series can be identified. The time series of these D k estimates often decreases to around a certain level after some time point. We finalize the value of K, if the D K estimate is close to the D K þ estimate. Otherwise, we suggest a larger K value and recalculate these D k estimates.
Our proposed method for estimating expected lifetime cost is a survival-adjusted cost estimator of Equation 1, in which the survival function is estimated from the rolling extrapolation algorithm and the monthly mean cost function is estimated using equation 7. We call our proposed rolling extrapolation survival-adjusted cost estimator the RESAC estimator. For comparison with the proposed RESAC estimator, we use the same notations to rewrite the annual mean costs function proposed in Etzioni et al. (2001) as the monthly mean cost function
We assign (
In this study, we consider that the Etzioni method is a survival-adjusted cost estimator of Equation 1 with the monthly mean cost function of Equation 8 and the best fitted Weibull model for survival extrapolation and denote it as the Etzioni-W estimator. We also define another estimator, denoted as Etzioni-R, by replacing the Weibull model fitted survival in the Etzioni-W estimator with the rolling extrapolation survival for performance comparison.
| SIMULATION STUDY

| Study designs
The survival times of subjects in an index population with a specific disease are generated from additive hazard models consisting of a reference hazard function and a hazard function reflecting the influence of the disease. The onset ages in years of 100,000 subjects in the index population are generated from a lognormal distribution, with mean log(55) and standard deviation log(1.1), with truncation at 40 and 70 years old. We randomly assign 60% of them as male. To generate data close to the real situation, the reference hazard function h r (x| age, sex) of a subject is given by the hazard function of an age-and sexmatched referent in the general population, which is calculated using the national life-table of Taiwan in the year 2000 (Hwang & Wang, 1999) . The additional hazard of death of a patient is often high right after diagnosis and quickly decreases to some level after some time point; then it either stabilizes around a constant level or continues to decrease after some time point, or increases over time (Andersson et al., 2013) . In practice, researchers often are not sure how the excess hazards would change beyond the maximum follow-up time. In the simulation study, we design three scenarios for the additional hazards to reflect the situations that patients' excess hazards are either constant, decreasing, or increasing after some time point. We use a combination of two Weibull hazard functions with different values of the model parameters to form additive hazard functions for the above three scenarios. Specifically, the additive hazard in month x since onset is presented as
where I(⋅) is an indicator and m is set at 12 months. The shape parameter γ 1 is set at 0.8 to reflect the fact that the hazard is sharply decreasing during the first 12 months. After month 12, the second shape parameters are set at γ 2 = 1.0, 0.5, and 1.5 to indicate the hazards of being constant, decreasing, and increasing, respectively, for the three scenarios. The corresponding scale parameters (λ 1 , λ 2 ) for the three scenarios are set at (1/80, 1/164), (1/60, 1/18), and (1/150, 1/1600), respectively, so that censoring rates are a little higher than 50% when the maximum follow-up time is set at 96 months. In summary, for a scenario with the values of these four parameters λ 1 , γ 1 , λ 2 , γ 2 , and the ith subject with onset age i and sex i in the index population, a survival time is generated from the hazard function h xjage i ; sex i ; λ 1 ; γ 1 ; λ 2 ; γ 2 ð Þ ¼ h r xjage i ; sex i ð Þþh a xjλ 1 ; γ 1 ; λ 2 ; γ 2 ð Þ :
For an illustration of Equation 10, we give the reference hazard function of a male aged 55 calculated from the national lifetable of Taiwan 2000 in Figure 1 , which shows it is gradually increasing. The hazard functions of male patients aged 55 with additive constant, decreasing, and increasing risks over time are also plotted in Figure 1 .
We use a design similar to that in Basu and Manning (2010) to generate monthly costs for the 100,000 patients, which are associated with the time point since diagnosis. Costs are expected to be high at the time of diagnosis and gradually decrease to a lower level after some time point. Costs are assumed to be stable over time until several months prior to death, when the costs start increasing and become the highest in the month that the subjects die (Brown, Riley, Schussler, & Etzioni, 2002) . Specifically, the costs for individual i in month j from diagnosis to the month of death, denoted by Y i , are generated using the cost-generating function
where A i , B i , D i are independent variables with uniform (0, 1), (0, 5), (0,10) distributions, respectively, and c ij = 0 for j > Y i . We set a = − 0.2 to reflect the costs that decrease from the diagnosis to a stable level in about 24 months. The value of b = 0.1 is chosen to simulate patients' expenditures that begin to increase at a time earlier than 12 months prior to their death. The costgenerating function generates a J-shaped cost structure similar to the simulation setup in Basu and Manning (2010) . For each simulation run, we first randomly choose complete data of 5,000 subjects without replacement from the generated index population. We further consider two conditions of assuming maximum follow-up time F = 96 and 120 months to form two index cohorts. With these designs, the observed data for analysis are survival times T i = min (Y i , U i , F) months with the censoring indicator δ i = I(T i = Y i ), where U i is an integer generated uniformly between 0 and max{Y i , i = 1, ... , 5000}, and the monthly costs c i1 ; :::; c iT i for i = 1 , 2 , . . . , 5000. For each scenario, we repeatedly generated 500 sets of complete data and censored data. The estimates of life expectancy and mean lifetime cost from each censored data set will be compared with the true ones from the complete data set.
| Results
We first compare performances of the proposed rolling extrapolation algorithm with the best fitted Weibull model in estimating life expectancy for the 500 simulated data sets in each scenario. To gain insight into the performance of the survival extrapolation approaches, we show lifetime survival functions estimated by the two methods on one simulated data set with 96 months of follow-up generated from scenario 1 of the excess constant hazard in Figure 2 . The extrapolated survival curve of the proposed algorithm was very close to the true survival curve for the simulated data, while the best fitted Weibull survival model had a clear overestimate. In fact, the predicted hazard function of the best fitted Weibull model was nearly a constant for the data set.
To choose proper values for B and K in the proposed monthly mean cost function of Equation 7, we calculated the mean expenditure of subjects at time k months prior to their death, D k , with B = 24. The time series plot of D k estimates shown in Figure Data S1 indicates that we can choose K = 36. For simplicity of implementing the analysis, we fixed B = 24 and K = 36 for the proposed RESAC estimator in the simulation studies. As shown in the right panel of Figure 2 , the extrapolation of the monthly mean costs of both the RESAC and the Etzioni-R estimator matched the increasing trend of the true mean costs over the lifetime horizon. The extrapolation of the mean cost functions in the Etzioni-W estimator was a flat curve beneath the true one, which was caused mainly by the nearly constant hazards predicted from the best fitted Weibull model. The results shown in Figure 2 indicate that the proposed RESAC estimator yielded quite accurate estimates of both the long-term survival and mean cost functions, while the Etzioni-W estimator had overestimated the survival function and underestimated the mean cost function.
To summarize the results of 500 simulated data sets for each scenario, we considered two evaluation parameters of mean relative absolute error (RAE) and coverage probability for performance comparison. The RAE of an estimate, which is calculated by the ratio between the absolute error and the true value, is used for measuring the accuracy of the estimator for a single run of the simulated data set. Mean RAE is the average of the RAE from the 500 simulated data sets. The coverage probability of an estimator is calculated by the proportion of the 95% CIs containing the true value in the 500 simulated data sets.
Shown in Table 1 , the average censoring rate of the 500 data sets simulated from scenario 1 of the excess constant hazard in the first condition of the maximum follow-up time set at 96 months was 53%. The true life expectancy was 124.5 months, while FIGURE 2 Extrapolation of survival functions and estimated mean cost functions using the proposed RESAC and Etzioni methods for a simulated data set with 96 months of follow-up, generated from scenario 1 of the excess constant hazard e338the mean estimates were 121.6 and 137.8 months using the proposed rolling extrapolation algorithm and the best fitted Weibull model, respectively. The mean RAE of the survival estimate using our proposed rolling extrapolation algorithm was 3.6%, while the Weibull model overestimated the life expectancy, with a mean RAE of 10.7%. The coverage probability of the estimator using the rolling extrapolation algorithm was 0.91, while that of the estimator using the best fitted Weibull model was 0.02. When the maximum follow-up time was extended to 120 months, the average censoring rate was 46%. The mean RAE of the life expectancy estimate of the rolling extrapolation algorithm declined to 2.2%, while the Weibull model still gave a high mean RAE of 9.7%. The coverage probability of the rolling method was 0.97, while it was still 0.01 for the Weibull model.
The results of the lifetime costs estimate for scenario 1 are shown in the bottom panel of Table 1 . The mean estimate of Etzioni-W was 131.6 for the condition of 96 months of maximum follow-up, which is higher than the true value of 125.6. The result indicates that the accuracy of Etzioni-W estimator was not too bad, with a mean RAE of 4.7%, but had a poor coverage probability of 0.19 in these simulated data. The mean RAE of the Etzioni-R estimator reduced to 2.7%, and coverage probability increased to 0.89. The more accurate survival estimates with the rolling extrapolation algorithm largely contributed to this improvement. With the proposed RESAC estimator, the mean RAE further decreased to 2.0%, while the coverage probability was 0.91. This small improvement can be attributed to using the proposed mean cost function of Equation 7. When the maximum follow-up time was extended to 120 months, as expected, we found better results for each of the three estimators and reached the same conclusion as that for the 96 months of follow-up. But the coverage probability of the Etzioni-W estimator was still far away from 0.95.
The simulation results for the other two scenarios of additive decreasing and increasing hazards are summarized in Tables Data S1 and S2. The proposed RESAC estimator for estimating lifetime costs performed the best, with mean RAEs below 2% and coverage probabilities around 0.97 for the data generated from the two scenarios. Similar to the findings shown in Table 1 , we found that the overall performance of the RESAC estimator is slightly better than that of the Etzioni-R estimator and much better than that of the Etzioni-W estimator for data simulated from the two scenarios of excess decreasing and increasing hazards. We concluded from the simulation studies that the excellent performance of the proposed RESAC estimator is attributable mainly to the accurate rolling extrapolation of survival function, while the proposed monthly mean cost function makes a relatively minor contribution.
| AN EXAMPLE USING REAL EMPIRICAL DATA
| Stroke cohorts
Taiwan established a National Health Insurance program, which is a single-payer, universal coverage system, in March 1995. Initially, it covered about 96% of people, and by 2009, it increased to more than 99% (Y. C. . The program features good accessibility and affordability and a comprehensive benefit package covering all medically necessary services (Cheng, 2003) . Acute stroke hospitalization during the first month is registered as a catastrophic illness, of which the diagnosis must be verified by two independent neurologists, and the copayment by the patient can be waived to relieve his or her financial burden. A recent validation study demonstrated the accuracy of diagnosis of ischemic stroke and comorbidities (Cheng, Kao, Lin, Lee, & Lai, 2011) . In general, costs are recorded each month without meaningful time lags. We used reimbursement data from Taiwan's National Health Insurance Research Database, which includes all inpatient and outpatient medical claims and prescription claims. Data on patients hospitalized for the first time during the 1998-1999 period for intracerebral hemorrhage (ICH) and ischemic stroke (IS) were retrieved from the National Health Insurance Research Database, including data on the follow-up of their vital status through the end of 2010. Summary statistics of clinical characteristics of the two cohorts are shown in Table 2 . The ICH cohort consists of 18,811 patients, with a mean age at diagnosis of 63 years old (interquartile range, 53 to 73). The mean age at diagnosis for the 63,176 patients with IS was 68 years old (interquartile range, 62 to 76). There are more male patients in the ICH cohort than in the IS cohort (63.9% vs. 57.8%). The censoring rate of the ICH cohort was 28.2% and that of the IS cohort was 26.8% for the maximum follow-up of 13 years. The median survival time of the ICH cohort was clearly lower than that of the IS cohort (58.8 months vs. 75.8 months) from diagnosis to the end of follow-up in 2010.
| Empirical validation
The validation of the proposed method was performed on the ICH and IS cohorts. We simulated two test data sets for the two cohorts under the assumption that the cohorts were followed to the end of 2004, that is, a maximum follow-up of 84 months. The censoring rates of the two test data sets were 43.1% and 47.0%, respectively. We applied the proposed method to these two test data sets to extrapolate the survival and predict the mean cumulative costs from diagnosis to the end of 2010. Because these two cohorts were actually followed until the end of 2010, the true estimates of the mean cumulative claims of 156 months for the cohorts can be considered as the benchmark for comparison. Shown in Figure S2 , the extrapolated survival functions of the proposed rolling extrapolation algorithm for the two cohorts are actually very close to the true ones. The survival curves extrapolated from the best fitted Weibull models indicate a slight overestimation in both cohorts. The results of survival extrapolation are given in Table 3 . The true mean survival times of the two cohorts during the 156 months of follow-up were 73.0 and 81.8 months. The estimates (95% CI) of the proposed method were 73.4 (72.2, 74.5) and 80.9 (80.2, 81.8) months, respectively. For the short-term extrapolations, the relative biases of the proposed algorithm were 0.5% and −1.0%, while those of the Weibull model were about 2.2%.
By examining the time series plot of the mean expenditure of subjects at months prior to their death calculated with B = 24, given in Figure S3 , we chose B = 24 and K = 36 for the proposed RESAC estimator. Plots of the cost extrapolations for the three estimators in the two test data sets, shown in Figure S4 , indicate that the extrapolations of these three estimators are close to the true ones, which moved around by small amounts over the period from 84 to 156 months. Summarized in Table 3 , we obtained an accurate estimate of the expected medical cost from diagnosis to 156 months, with a relative bias of about 1.7% for the ICH cohort. Etzioni-R and Etzioni-W estimators gave an overestimate, with relative biases of about 5.3% and 4.7%, respectively. The 95% CI of the RESAC estimator covered the true value, while the 95% CIs of the other two estimators did not contain the true value. For the test data of the IS cohort, all the three estimators performed satisfactorily. The relative biases of the estimators were 1.2% for the RESAC, 1.3% for the Etzioni-R, and 1.2% for the Etzioni-W. The 95% CIs of the three estimators covered the true values for the two cohorts.
These results indicate that the short-term survival extrapolation using the best fitted Weibull model was not as accurate as the rolling extrapolation algorithm, but very close. Hence, we obtained very close estimates of the mean cumulative costs from the Etzioni-W and Etzioni-R estimators. The more accurate results from the RESAC estimator for the test data set of the ICH cohort is attributable to using the proposed monthly mean cost function with K = 36 months, instead of K = 11 in Etzioni method.
| Lifetime medical cost estimation
Although the accuracy of the short-term survival extrapolation of the Weibull model seems acceptable, we further demonstrate its potential problem in long-term extrapolation and consequent influence on lifetime cost estimation using these two real data sets. Using the rolling extrapolation algorithm and the best fitted Weibull model, we extrapolated survival functions of the two cohorts beyond the maximum follow-up of 156 months, or 13 years. The survival extrapolations using the best fitted Weibull model shown in Figure 3 indicated that it was unreasonably high. The extrapolated survival rates beyond 450 months for patients in the ICH cohort were even higher than the survival rates of an age-and sex-matched reference population. The extrapolations resulted in life expectancy estimates of 152.9 and 126.7 months, shown in Figure 4 and Table S3 , for ICH and IS cohorts, respectively. The proposed rolling extrapolation algorithm gave very close life expectancy estimates of 107.5 and 107.1 months, respectively, for the two cohorts. The plots in Figure S5 indicated that we can choose B = 24 and K = 36 for the proposed RESAC estimator. The proposed method gave the mean lifetime medical cost for the ICH patients after diagnosis an estimate of NT$ 1,119,423, which is approximately US$ 35,000. The 95% CI of the estimate was around US$ 33,900-36,000. Shown also in Figure 4 and Table S3 , the mean lifetime cost estimates of Etzioni-W estimator were much higher than those of Etzioni-R estimator, which were close to those of the RESAC estimator for the ICH cohort. This is caused mainly by the overestimates of survival from the best fitted Weibull model. The estimate (95% CI) of the mean lifetime medical cost for the patients with IS after diagnosis using the proposed RESAC estimator was NT$ 1,126, 428, which is approximately US$ 35, 200 (34, 700) . Similarly, the higher lifetime cost estimate of the Etzioni-W for the IS cohort was related mainly to the overestimates of survival from the best fitted Weibull model. FIGURE 3 Lifetime survival extrapolations from the maximum follow-up of 156 months of the intracerebral hemorrhage (ICH) and ischemic stroke (IS) cohorts, using the rolling extrapolation algorithm and the best fitted Weibull models. Survival curves of reference were estimated from survival data generated for age-and sex-matched referents who did not have a stroke
We have presented a method for estimating the expected lifetime medical cost of patients diagnosed with a specific disease when follow-up data of survival and cost are censored. The general formula for estimating lifetime medical cost, first proposed by Etzioni et al. (2001) , is a sum of the product of estimated complete survival and cost functions. We have demonstrated that the proposed method of survival and lifetime costs extrapolation outperformed Etzioni's method using simulated data with various scenarios and empirical data of a nationwide patient cohort of stroke. We did not make a direct comparison of performance with the popular approaches, such as reweighted estimators and the refined model of Basu and Manning (2010) , which focus on censoring for estimates of costs over a restricted period rather than lifetime costs. While our proposed method may be relatively complicated in computation, we have written a package of R programs, which is available at http://www.stat.sinica.edu.tw/isqol, for applied researchers to implement in practice. The gain of the proposed method is contributed mainly by the rolling extrapolation algorithm, which produced a more accurate estimate of the lifetime survival function. In contrast, as demonstrated in the simulated data and the real data, perfectly fitted parametric survival models may not produce a reliable long-term extrapolation. Consequently, accuracy of the extrapolated cost functions was affected. The much better performance of the rolling extrapolation algorithm over the best fitted parametric models is first attributable to using the external data of vital statistics. Second, because the logit transformation of the relative survival function between the index cohort and the borrowed reference cohort is a flattened curve and will approach a straight line after a certain time point, the nearly straight curve is favorable to a rolling forecast. We have taken advantage of this linearity property to propose a rolling extrapolation algorithm that performs satisfactorily in accuracy and robustness from simulated data, with the index cohorts having excess constant, decreasing, or increasing hazards beyond follow-up.
In practice, mainly due to the small cohort size, the observed logit W(t) values at the last few months to the maximum follow-up time may vary away from the decreasing linear trend. This may cause the proposed rolling algorithm to produce less accurate extrapolations. We suggest that users examine the plot of the observed logit W(t) curve to see if there are any unusual deviations at the time near the maximum follow-up. If deviations after a time point are identified, we suggest starting the rolling extrapolation earlier, at that identified time point, instead of at the maximum follow-up time. In our R package for the proposed method, we have included a function of detecting the abnormal change of curvatures of the observed logit W(t) curve to help identify the time point for starting the extrapolation.
Medical expenditures are usually higher for patients in the final months or years prior to their death. The time near mortality when costs begin to increase is also crucial to the accurate extrapolation of the costs function in the survival-adjusted cost estimator. Instead of using a fixed time, as in the Etzioni method, we propose examining the time series plot of the mean expenditure of subjects in the months prior to their death to choose the time point. We have shown that allowing data to determine from which month prior to death to be included in the monthly mean cost function also makes a significant contribution to the accuracy of the estimator.
Finally, the survival-adjusted cost estimator has been criticized for having a large bias when aggregated data are available only for large time intervals, ignoring censoring within the intervals. Although the estimator is unbiased theoretically when the intervals become infiniteness small (O'Hagan & Stevens, 2004) , it was not clear how small the intervals must be for using the survival-adjusted cost estimator in practice. In this study, we applied the proposed estimator to monthly real data and simulated data for evaluation and found that the biases are acceptably small. As monthly data are increasingly available in many institutions and countries, we expect that the proposed method and R package for estimating the mean lifetime cost would benefit researchers in related fields.
FIGURE 4
The estimates of life expectancy and mean lifetime costs using the proposed RESAC and Etzioni methods for intracerebral hemorrhage (ICH) and ischemic stroke (IS) cohorts with13 years of follow-up. The vertical segment represents the 95% confidence interval and the within-tick is the mean e342
